Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

M. Teresa Cedena; Inmaculada Rapado; Alejandro Santos-Lozano; Rosa Ayala; Esther Onecha; María Abaigar; Esperanza Such; Fernando Ramos; José Cervera; María Díez-Campelo; Guillermo Sanz; Jesús Hernández Rivas; Alejandro Lucía; Joaquin Martínez-López

doi:10.18632/oncotarget.25856

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

PDF | How to cite

Oncotarget. 2018; 9:30936-30936. https://doi.org/10.18632/oncotarget.25856

Metrics: PDF 1497 views | ?

M. Teresa Cedena^1,2,*, Inmaculada Rapado^1,2,*, Alejandro Santos-Lozano^2,3, Rosa Ayala^1,2, Esther Onecha^1,2 María Abaigar⁴, Esperanza Such⁵, Fernando Ramos⁶, José Cervera^5,7, María Díez-Campelo^4,8, Guillermo Sanz⁵, Jesús Hernández Rivas^4,8, Alejandro Lucía^2,9 and Joaquin Martínez-López^1,2

¹ Hematology Department, Hospital Universitario 12 Octubre, CNIO, Universidad Complutense, Madrid, Spain
² Research Institute of Hospital 12 de Octubre (‘i+12’), Madrid, Spain
³ GIDFYS, European University Miguel de Cervantes, Valladolid, Spain
⁴ IBSAL, Cancer Research Center (USAL-CSIC), Salamanca, Spain
⁵ Hematology Department, Hospital Universitario La Fe, Valencia, Spain
⁶ Hematology Department, Hospital Universitario de León, and IBIOMED, Universidad León, León, Spain
⁷ Genetics Unit, Hospital Universitario La Fe, Valencia, Spain
⁸ Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
⁹ Universidad Europea de Madrid, Madrid, Spain
^* These authors have contributed equally to this work

Published: July 20, 2018

This article has been corrected: In the Materials and Methods section, the data access link is incorrect. In addition, reference 37 was also listed incorrectly. The proper information is given below:

Materials and Methods: The data discussed in this publication have been deposited in the NCBI Sequence Read Archive (SRA) [37] and are accessible through (http://www.ncbi.nlm.nih.gov/sra/SRP102906).

References: 37. Leinonen R, Sugawara H, Shumway M. The sequence read archive. Nucleic Acids Res. 2011; 39 (Database issue): D19-D21.

Original article: Oncotarget. 2017; 8:106948-106961. DOI: https://doi.org/10.18632/oncotarget.22157.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25856

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes